<DOC>
	<DOCNO>NCT00683501</DOCNO>
	<brief_summary>A Multi-Centre , Double-Blind , Randomised , Parallel-Group , Placebo-Controlled Phase 1I Study Investigate Safety , Efficacy , Pharmacokinetic Profile Twice-Daily DNB-001 Previously Untreated Patients intraocular Hypertension</brief_summary>
	<brief_title>Safety , Efficacy , Pharmacokinetic Profile DNB-001 Subjects With Elevated Intraocular Pressure</brief_title>
	<detailed_description>To evaluate efficacy four dosage mg DNB-001 administered twice daily ( bid ) per o ( p.o . ) anti-ocular hypertensive agent , compare placebo administer bid po , 28 day , patient ocular hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Male female , least 18 year old , general good health , presently treat elevate intraocular pressure ( IOP ) , best correct Early Treatment Diabetic Retinopathy Study ( ETDRS ) visual acuity score equivalent Snellen score 20/50 good eye lOP 21 29 mm Hg baseline . Use intraocular pressure lower medication within past 3 month history ocular surgery glaucoma Evidence potential angle closure gonioscopy Abnormal optic disc visual field consistent glaucoma Use topical ocular medication study evidence systemic disease might interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>ocular hypertension</keyword>
	<keyword>elevate IOP</keyword>
	<keyword>glaucoma</keyword>
	<keyword>neuroprotection</keyword>
</DOC>